https://www.selleckchem.com/pr....oducts/cyclo-rgdyk.h
012). The survival rates after R0, R1 and R2 (non-resected metastases) resection were 21% (n = 33), 0% (n = 4) and 17% (n = 11), respectively (p = 0.273). Oligometastatic EGAC is associated with poor overall survival even after complete resection of all tumor manifestations. The subgroup of patients with a complete histologic response of metastatic lesions to neoadjuvant FLOT shows 5-year survival rates similar to non-metastatic EGAC. Trial registration Not applicable. Oligometastatic EGAC is associated with poor overall survival ev
Gefällt mir
Kommentar
Teilen
